IQVIA Holdings Inc
IQV
ISIN null / Valor 39103858
IQVIA Holdings Inc
UMushroom community rating:
About company
IQVIA Holdings Inc. is a global provider of clinical research, data and technology services to the life sciences and healthcare industries. The company operates a contract research organization (CRO) business that designs and runs clinical trials, manages sites and supports patient recruitment, alongside a business that aggregates and analyzes large healthcare datasets to generate real‑world evidence, market intelligence and outcomes research for pharmaceutical, biotech, medical device and payer clients. IQVIA also offers software and technology-enabled commercial solutions, regulatory and market-access consulting, and analytics platforms that integrate claims, prescription and electronic medical record data to support development, commercialization and post‑market activities. Headquartered in Durham, North Carolina, IQVIA was formed from the combination of Quintiles and IMS Health and operates internationally as a publicly traded company.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (29.08.2026):
IQVIA Holdings Inc.'s second quarter 2026 (Q2 2026) results showed broad-based growth: revenue of $4,368 million (up 8.7% year‑over‑year), GAAP net income of $256 million, adjusted EBITDA of $994 million (up 9.2% YoY), and adjusted diluted EPS of $3.15 (up 12.1% YoY). The company raised full‑year 2026 guidance and reported strong bookings, cash flow and continued operational momentum across both segments.
Revenue
Q2 2026 revenue was $4,368M, up 8.7% reported (8.5% at constant currency). Commercial Solutions: $1,793M (+8.6%); Research & Development Solutions: $2,575M (+8.8%).
Profitability
GAAP net income for Q2 2026 was $256M. Adjusted EBITDA was $994M, a 9.2% increase year‑over‑year.
Earnings per Share
GAAP diluted EPS was $1.53 for Q2 2026. Adjusted diluted EPS was $3.15, up 12.1% year‑over‑year.
Bookings and Backlog
R&DS net new bookings in Q2 were $3.15B (+19% YoY) with a book‑to‑bill of 1.22x. LTM net new bookings were $11.3B (+13% YoY). R&DS contracted backlog was $34.2B, with ~$9.2B expected to convert to revenue in the next 12 months (≈+7.5% YoY).
Cash Flow
Operating cash flow in Q2 2026 was $558M (+26.0% YoY) and free cash flow was $360M (+23.3% YoY).
Guidance
IQVIA raised full‑year 2026 guidance: revenue $17,275–17,475M, adjusted EBITDA $4,000–4,050M, and adjusted diluted EPS $12.80–13.00. The new revenue mid‑point implies ~6.5% growth (vs prior 5.8%).
Balance Sheet & Leverage
As of June 30, 2026, cash and equivalents were $1,909M, gross debt $15,999M, net debt $14,090M, and net leverage ratio 3.59x LTM adjusted EBITDA.
Capital Allocation
IQVIA repurchased $398M of common stock in Q2 ( $950M year‑to‑date) and had $2,819M of repurchase authorization remaining as of June 30, 2026.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
44075 M
Market cap (USD)
1,197,937
Daily traded volume (Shares)
198.33 / 194.63
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
